Your browser doesn't support javascript.
loading
Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma.
Costa, Ana; Thirant, Cécile; Kramdi, Amira; Pierre-Eugène, Cécile; Louis-Brennetot, Caroline; Blanchard, Orphée; Surdez, Didier; Gruel, Nadege; Lapouble, Eve; Pierron, Gaëlle; Sitbon, Deborah; Brisse, Hervé; Gauthier, Arnaud; Fréneaux, Paul; Bohec, Mylène; Raynal, Virginie; Baulande, Sylvain; Leclere, Renaud; Champenois, Gabriel; Nicolas, Andre; Meseure, Didier; Bellini, Angela; Marabelle, Aurelien; Geoerger, Birgit; Mechta-Grigoriou, Fatima; Schleiermacher, Gudrun; Menger, Laurie; Delattre, Olivier; Janoueix-Lerosey, Isabelle.
Afiliação
  • Costa A; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Thirant C; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • Kramdi A; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Pierre-Eugène C; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • Louis-Brennetot C; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Blanchard O; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • Surdez D; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Gruel N; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • Lapouble E; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Pierron G; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • Sitbon D; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Brisse H; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • Gauthier A; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Fréneaux P; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • Bohec M; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Raynal V; Department of Translational Research, Institut Curie, Paris, France.
  • Baulande S; Unité de Génétique Somatique, Institut Curie, Paris, France.
  • Leclere R; Unité de Génétique Somatique, Institut Curie, Paris, France.
  • Champenois G; Unité de Génétique Somatique, Institut Curie, Paris, France.
  • Nicolas A; Department of Imaging, PSL Research University, Institut Curie, Paris, France.
  • Meseure D; Department of Biopathology, Institut Curie, Paris, France.
  • Bellini A; Department of Biopathology, Institut Curie, Paris, France.
  • Marabelle A; Genomics of Excellence (ICGex) Platform, Institut Curie, Paris, France.
  • Geoerger B; Inserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
  • Mechta-Grigoriou F; Genomics of Excellence (ICGex) Platform, Institut Curie, Paris, France.
  • Schleiermacher G; Genomics of Excellence (ICGex) Platform, Institut Curie, Paris, France.
  • Menger L; Department of Biopathology, Institut Curie, Paris, France.
  • Delattre O; Department of Biopathology, Institut Curie, Paris, France.
  • Janoueix-Lerosey I; Department of Biopathology, Institut Curie, Paris, France.
J Immunother Cancer ; 10(8)2022 08.
Article em En | MEDLINE | ID: mdl-36054452
ABSTRACT

BACKGROUND:

High-risk neuroblastoma is a pediatric cancer with still a dismal prognosis, despite multimodal and intensive therapies. Tumor microenvironment represents a key component of the tumor ecosystem the complexity of which has to be accurately understood to define selective targeting opportunities, including immune-based therapies.

METHODS:

We combined various approaches including single-cell transcriptomics to dissect the tumor microenvironment of both a transgenic mouse neuroblastoma model and a cohort of 10 biopsies from neuroblastoma patients, either at diagnosis or at relapse. Features of related cells were validated by multicolor flow cytometry and functional assays.

RESULTS:

We show that the immune microenvironment of MYCN-driven mouse neuroblastoma is characterized by a low content of T cells, several phenotypes of macrophages and a population of cells expressing signatures of myeloid-derived suppressor cells (MDSCs) that are molecularly distinct from the various macrophage subsets. We document two cancer-associated fibroblasts (CAFs) subsets, one of which corresponding to CAF-S1, known to have immunosuppressive functions. Our data unravel a complex content in myeloid cells in patient tumors and further document a striking correspondence of the microenvironment populations between both mouse and human tumors. We show that mouse intratumor T cells exhibit increased expression of inhibitory receptors at the protein level. Consistently, T cells from patients are characterized by features of exhaustion, expressing inhibitory receptors and showing low expression of effector cytokines. We further functionally demonstrate that MDSCs isolated from mouse neuroblastoma have immunosuppressive properties, impairing the proliferation of T lymphocytes.

CONCLUSIONS:

Our study demonstrates that neuroblastoma tumors have an immunocompromised microenvironment characterized by dysfunctional T cells and accumulation of immunosuppressive cells. Our work provides a new and precious data resource to better understand the neuroblastoma ecosystem and suggest novel therapeutic strategies, targeting both tumor cells and components of the microenvironment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transcriptoma / Neuroblastoma Limite: Animals / Child / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transcriptoma / Neuroblastoma Limite: Animals / Child / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França